In the USA in 2016, 134,490 cases of colorectal cancer (CRC) will be diagnosed and 49,190 people will die from this disease [1]. Contributors to CRC risk for patients include age, family history, and race, as well as potentially modifiable factors such as diet, the intestinal microbiome, socioeconomic factors, physical activity, and screening utilization rates [2][3][4]. Screening, in particular, can reduce CRC mortality due to the identification and removal of precursor adenomas and potentially curable early-stage cancers; screening efficacy is manifest in the reduced CRC incidence in the USA attributed to increasing screening rates among the population [2,3]. Colonoscopic CRC surveillance likely further contributes to reduced CRC incidence and CRC-related death, particularly for patients with prior colonic neoplasms, or patients with a strong family history whether or not they have undergone any genetic evaluation for a familial syndrome.The distribution of CRC deaths is not linear with age, with 79.1 % of deaths occurring after age 60 (Table 1) [1]. Indeed, age is a very powerful predictor for the development of precursor adenomas and CRC, with approximately 94.5 % of all CRCs occurring after age 50, the age at which universal CRC screening is recommended for men and women [2], although 5.5 % of all CRCs occur before age 50, when general screening is not offered or recommended unless there is a strong family history of CRC, when screening is recommended to commence at age 40 [2,3]. Over a 25-year period in a cohort of nearly 400,000 CRC patients, the incidence of CRC was reduced by 0.92 %, although this decline only occurred in subjects [age 50, and largely attributed to screening implementation [5]. Following current trends, the incidence of colon and rectal cancer are projected to increase 124 and 90 % in subjects aged 20-34 and 27.7 and 46.0 % in subjects aged 35-49, respectively, by 2030 [5], with rectal cancer diagnosed in about two-thirds of patients \50 years [6]. While these trends are alarming, the absolute number of CRC patients in the \50 years group is still relatively small (Table 1); however, their proportion will increase relatively with continued successful screening and subsequent declines in CRC incidence among the [50 years group. Moreover, vigilance for a potentially inherited form of CRC must be strongly considered when a patient aged \50 years is diagnosed with this disease [7]. At present, other than heightened vigilance and evaluation of patients with a strong family history of cancer, there is no current screening strategy to address this \50 years group since it is not cost-effective as with the [age 50 years group [8].Like age, the distribution of and risk of CRC among racial and ethnic groups are not identical, with a clear disparity for African Americans for CRC incidence and death (Table 2) [1,2,9]. In conjunction with the higher incidence and death rates, African American CRC patients are initially diagnosed as many as 5-8 years earlier in age (median age of first diagnosis for...